Evidence map›Paper›PMID 42889508›Full record

ArticleComputational and structural biotechnology journal2026

Computational Design of a TCR-like Human V

Tae-Sung Oh, Seong-Woo Kim, SangPhil Ahn, Seonghyuk Suh, JooYeon Lee, YeongNam Bae, Hyejin Lee, Yong-Sung Kim, Bo-Seong Jeong, Byung-Ha Oh

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tae-Sung OhTherazyne, Inc., Daejeon, Republic of Korea.
Seong-Woo KimDepartment of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.ORCID https://orcid.org/0000-0002-4374-2093
SangPhil AhnTherazyne, Inc., Daejeon, Republic of Korea.ORCID https://orcid.org/0009-0007-1277-8679
Seonghyuk SuhTherazyne, Inc., Daejeon, Republic of Korea.ORCID https://orcid.org/0009-0000-2363-0812
JooYeon LeeTherazyne, Inc., Daejeon, Republic of Korea.
YeongNam BaeDepartment of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.ORCID https://orcid.org/0009-0006-9717-4112
Hyejin LeeTherazyne, Inc., Daejeon, Republic of Korea.ORCID https://orcid.org/0009-0006-1839-9752
Yong-Sung KimDepartment of Molecular Science and Technology, College of Advanced Bioconvergence Engineering, Ajou University, Suwon, Republic of Korea.ORCID https://orcid.org/0000-0003-2673-1509
Bo-Seong JeongTherazyne, Inc., Daejeon, Republic of Korea.ORCID https://orcid.org/0000-0003-0629-6722
Byung-Ha OhTherazyne, Inc., Daejeon, Republic of Korea.ORCID https://orcid.org/0000-0002-6437-8470

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell receptor (TCR)-like antibodies that recognize a peptide-major histocompatibility complex (pMHC) can enable precise targeting of cancer cells, but developing single-domain binders with high specificity and affinity is challenging. Here, we report the computational design and experimental validation of a TCR-like human heavy chain variable (V

Identifiers

PMID42889508
PMCPMC13669508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.